August 13, 2020 – Thermo Fisher Scientific Inc. (Waltham, MA) announced that its offer to acquire all of the ordinary shares of QIAGEN N.V. has lapsed.
Based on information provided by the settlement agents for the offer, the minimum acceptance threshold condition to the offer was not satisfied and the offer has lapsed in accordance with its terms.
As a result, Thermo Fisher has terminated the acquisition agreement with QIAGEN, and QIAGEN will pay to Thermo Fisher an expense reimbursement payment of $95 million in cash in accordance with the terms of the acquisition agreement.
